To date, disease-causing mutations have been identified in 17 genes (4), with three genes (KCNQ1, KCNH2, and SCN5A) accounting for over 90% of genotype-positive patients (5), Risk stratification in LQTS patients is important for optimizing patient care and clinical decision regarding treatment, especially the decision to implant implantable cardioverter defibrillators (ICD) in young patients with lifetime risk of complications (6, 7). Here, SCN5A is linked to familial long QT syndrome.